Cargando…

Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design

The study aimed to develop a new reverse-phase high-performance liquid chromatography (RP-HPLC) method with diode array detection (DAD) detection for simultaneous estimation of escitalopram (EST) and clonazepam (CZP) in tablet dosage forms with a quality by design (QbD) approach. The chromatographic...

Descripción completa

Detalles Bibliográficos
Autores principales: Foudah, Ahmed I., Alshehri, Sultan, Shakeel, Faiyaz, Alqarni, Mohammed H., Aljarba, Tariq M., Alam, Prawez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268709/
https://www.ncbi.nlm.nih.gov/pubmed/35807458
http://dx.doi.org/10.3390/molecules27134209
_version_ 1784744051764887552
author Foudah, Ahmed I.
Alshehri, Sultan
Shakeel, Faiyaz
Alqarni, Mohammed H.
Aljarba, Tariq M.
Alam, Prawez
author_facet Foudah, Ahmed I.
Alshehri, Sultan
Shakeel, Faiyaz
Alqarni, Mohammed H.
Aljarba, Tariq M.
Alam, Prawez
author_sort Foudah, Ahmed I.
collection PubMed
description The study aimed to develop a new reverse-phase high-performance liquid chromatography (RP-HPLC) method with diode array detection (DAD) detection for simultaneous estimation of escitalopram (EST) and clonazepam (CZP) in tablet dosage forms with a quality by design (QbD) approach. The chromatographic conditions were optimized by Box-Behnken design (BBD) and developed method was validated for the linearity, system suitability, accuracy, precision, robustness, sensitivity, and solution stability according to International Council for Harmonization (ICH) guidelines. EST and CZP standard drugs peaks were separated at retention times of 2.668 and 5.046 min by C-18 column with dimension of 4.6 × 100 mm length and particle size packing 2.5 µm. The mobile phase was methanol: 0.1% orthophosphoric acid (OPA) (25:75, v/v), with a flow rate of 0.7 mL/min at temperature of 26 °C. The sample volume injected was 20 µL and peaks were detected at 239 nm. Using the standard calibration curve, the % assay of marketed tablet was founded 98.89 and 98.76 for EST and CZP, respectively. The proposed RP-HPLC method was able to detect EST and CZP in the presence of their degradation products, indicating the stability-indicating property of the developed RP-HPLC method. The validation parameter’s results in terms of linearity, system suitability, accuracy, precision, robustness, sensitivity, and solution stability were in an acceptable range as per the ICH guidelines. The newly developed RP-HPLC method with QbD application is simple, accurate, time-saving, and economic.
format Online
Article
Text
id pubmed-9268709
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92687092022-07-09 Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design Foudah, Ahmed I. Alshehri, Sultan Shakeel, Faiyaz Alqarni, Mohammed H. Aljarba, Tariq M. Alam, Prawez Molecules Article The study aimed to develop a new reverse-phase high-performance liquid chromatography (RP-HPLC) method with diode array detection (DAD) detection for simultaneous estimation of escitalopram (EST) and clonazepam (CZP) in tablet dosage forms with a quality by design (QbD) approach. The chromatographic conditions were optimized by Box-Behnken design (BBD) and developed method was validated for the linearity, system suitability, accuracy, precision, robustness, sensitivity, and solution stability according to International Council for Harmonization (ICH) guidelines. EST and CZP standard drugs peaks were separated at retention times of 2.668 and 5.046 min by C-18 column with dimension of 4.6 × 100 mm length and particle size packing 2.5 µm. The mobile phase was methanol: 0.1% orthophosphoric acid (OPA) (25:75, v/v), with a flow rate of 0.7 mL/min at temperature of 26 °C. The sample volume injected was 20 µL and peaks were detected at 239 nm. Using the standard calibration curve, the % assay of marketed tablet was founded 98.89 and 98.76 for EST and CZP, respectively. The proposed RP-HPLC method was able to detect EST and CZP in the presence of their degradation products, indicating the stability-indicating property of the developed RP-HPLC method. The validation parameter’s results in terms of linearity, system suitability, accuracy, precision, robustness, sensitivity, and solution stability were in an acceptable range as per the ICH guidelines. The newly developed RP-HPLC method with QbD application is simple, accurate, time-saving, and economic. MDPI 2022-06-30 /pmc/articles/PMC9268709/ /pubmed/35807458 http://dx.doi.org/10.3390/molecules27134209 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Foudah, Ahmed I.
Alshehri, Sultan
Shakeel, Faiyaz
Alqarni, Mohammed H.
Aljarba, Tariq M.
Alam, Prawez
Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design
title Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design
title_full Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design
title_fullStr Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design
title_full_unstemmed Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design
title_short Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design
title_sort simultaneous estimation of escitalopram and clonazepam in tablet dosage forms using hplc-dad method and optimization of chromatographic conditions by box-behnken design
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268709/
https://www.ncbi.nlm.nih.gov/pubmed/35807458
http://dx.doi.org/10.3390/molecules27134209
work_keys_str_mv AT foudahahmedi simultaneousestimationofescitalopramandclonazepamintabletdosageformsusinghplcdadmethodandoptimizationofchromatographicconditionsbyboxbehnkendesign
AT alshehrisultan simultaneousestimationofescitalopramandclonazepamintabletdosageformsusinghplcdadmethodandoptimizationofchromatographicconditionsbyboxbehnkendesign
AT shakeelfaiyaz simultaneousestimationofescitalopramandclonazepamintabletdosageformsusinghplcdadmethodandoptimizationofchromatographicconditionsbyboxbehnkendesign
AT alqarnimohammedh simultaneousestimationofescitalopramandclonazepamintabletdosageformsusinghplcdadmethodandoptimizationofchromatographicconditionsbyboxbehnkendesign
AT aljarbatariqm simultaneousestimationofescitalopramandclonazepamintabletdosageformsusinghplcdadmethodandoptimizationofchromatographicconditionsbyboxbehnkendesign
AT alamprawez simultaneousestimationofescitalopramandclonazepamintabletdosageformsusinghplcdadmethodandoptimizationofchromatographicconditionsbyboxbehnkendesign